News

Latest News

Desktop and Tablet

Andira Pharmaceuticals Secures Exclusive Worldwide License for Cannabinoid Antibiotics and Drug Delivery Systems

Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors

Read more

Andira Pharmaceuticals welcomes pioneering cannabinoid researcher and board-certified neurologist Ethan Russo, MD, to its Board of Directors

Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model. Andira

Read more

Positive International Search Report & Written Opinion (ISR/WO) on PCT Patent Application: “Antibiotic Cannabinoid-Terpene Formulations”

Vancouver, British Columbia, Canada– To protect novel anti-infective formulations developed at The University of British Columbia (UBC) for the treatment of Enterococcus, including the multi-drug-resistant superbug VRE, a Patent Cooperation Treaty (PCT) application entitled “Antibiotic Cannabinoid-Terpene Formulations” was filed in May 2020. The International Search Report & Written Opinion (ISR/WO)

Read more

Mobile Only

Andira Pharmaceuticals Secures Exclusive Worldwide License for Cannabinoid Antibiotics and Drug Delivery Systems

Vancouver, July 7, 2021– Andira Pharmaceuticals today announces it has secured an exclusive worldwide license for a portfolio of three cannabinoid antibiotic technologies along with their complementary drug delivery systems designed to prevent and treat multi-drug resistant infections. The license was granted by the University of British Columbia (UBC). Inventors

Read more

Andira Pharmaceuticals welcomes pioneering cannabinoid researcher and board-certified neurologist Ethan Russo, MD, to its Board of Directors

Vancouver, British Columbia, Canada– Andira Pharmaceuticals welcomes to its board of directors, Dr. Ethan Russo, a global pioneer in the development of cannabinoid therapeutics. Andira is a privately-held biopharmaceutical firm dedicated to the advancement of cannabinoid-based therapeutics for infectious disease and oncology indications in the traditional pharmaceutical business model. Andira

Read more

Positive International Search Report & Written Opinion (ISR/WO) on PCT Patent Application: “Antibiotic Cannabinoid-Terpene Formulations”

Vancouver, British Columbia, Canada– To protect novel anti-infective formulations developed at The University of British Columbia (UBC) for the treatment of Enterococcus, including the multi-drug-resistant superbug VRE, a Patent Cooperation Treaty (PCT) application entitled “Antibiotic Cannabinoid-Terpene Formulations” was filed in May 2020. The International Search Report & Written Opinion (ISR/WO)

Read more